[149] demonstrated that silencing transglutaminase-2 (TG2) using CRISPR–Cas9 can affect the transcriptional regulation of MUC1 by inhibiting androgen receptor (AR) expression, leading to androgen insensitivity and malignancy in PCa cells. This evidence concerns the gene AR and posterior cortical atrophy.